A detailed history of Black Rock Inc. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 8,383,910 shares of MRSN stock, worth $18.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,383,910
Previous 8,095,729 3.56%
Holding current value
$18.6 Million
Previous $36.3 Million 53.54%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.0 - $4.45 $576,362 - $1.28 Million
288,181 Added 3.56%
8,383,910 $16.9 Million
Q1 2024

May 10, 2024

BUY
$2.16 - $5.94 $543,125 - $1.49 Million
251,447 Added 3.21%
8,095,729 $36.3 Million
Q4 2023

Feb 13, 2024

SELL
$1.11 - $2.34 $142,499 - $300,404
-128,378 Reduced 1.61%
7,844,282 $18.2 Million
Q3 2023

Nov 13, 2023

BUY
$1.06 - $3.91 $9,198 - $33,930
8,678 Added 0.11%
7,972,660 $10.1 Million
Q2 2023

Aug 11, 2023

BUY
$3.08 - $9.55 $1.51 Million - $4.68 Million
490,160 Added 6.56%
7,963,982 $26.2 Million
Q1 2023

May 12, 2023

SELL
$4.0 - $7.02 $72,428 - $127,111
-18,107 Reduced 0.24%
7,473,822 $30.7 Million
Q4 2022

Feb 13, 2023

BUY
$5.65 - $7.86 $2.28 Million - $3.17 Million
403,842 Added 5.7%
7,491,929 $43.9 Million
Q3 2022

Nov 14, 2022

SELL
$4.63 - $8.0 $8.3 Million - $14.3 Million
-1,792,932 Reduced 20.19%
7,088,087 $47.9 Million
Q2 2022

Aug 12, 2022

BUY
$2.84 - $5.0 $3.56 Million - $6.27 Million
1,254,823 Added 16.45%
8,881,019 $41 Million
Q1 2022

May 12, 2022

BUY
$3.74 - $6.63 $549,656 - $974,391
146,967 Added 1.97%
7,626,196 $30.4 Million
Q4 2021

Feb 10, 2022

SELL
$5.48 - $9.86 $7.28 Million - $13.1 Million
-1,328,099 Reduced 15.08%
7,479,229 $46.5 Million
Q3 2021

Nov 09, 2021

SELL
$8.56 - $14.47 $131,618 - $222,490
-15,376 Reduced 0.17%
8,807,328 $83.1 Million
Q2 2021

Aug 11, 2021

BUY
$13.28 - $18.07 $117 Million - $159 Million
8,822,704 New
8,822,704 $120 Million

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $216M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.